AXT's Liquidity Supports InP Capacity Expansion: Can Growth Continue?

AXT ended Q2 with $748.8 million of cash, cash equivalents and investments after its April secondary offering, supporting plans to double indium phosphide capacity in 2026 and expand again in 2027. Record Q2 revenue of $47.6 million and a 44.9% GAAP gross margin, alongside an InP backlog above $100 million and long-term customer commitments, underpin consensus forecasts for 2026 and 2027 revenue growth of 146.4% and 108.4%, respectively. Risks include accelerating internal InP capacity additions by Coherent and Lumentum, which could reduce their sourcing from AXT, while AXTI trades at an elevated 11.99x forward sales versus the semiconductor-industry average of 4.94x.

Analysis

The key underwriting issue is not wafer scarcity but whether AXTI can preserve merchant-substrate economics as major customers internalize production. COHR and LITE are simultaneously customers, competitors and potential sources of future order volatility; their internal ramps could convert today's capacity reservations into lower external purchasing intensity by 2027-28. This makes reported backlog a weaker indicator of durable revenue than shipment schedules, take-or-pay terms, qualification status and customer-specific mix.

The equity now discounts an unusually narrow execution path: capacity must come online on time, yields must remain high during scale-up, and AI-optics demand must absorb new industry supply without price erosion. A shift toward 6-inch InP wafers can improve throughput but also lowers the strategic value of smaller-scale merchant supply if vertically integrated players reach adequate yields. Margin risk will likely emerge before revenue risk, through pricing concessions or under-absorption during new-fab ramps.

There is also a material data-validation issue: the stated liquidity and financing figures appear disproportionate to AXTI's historical scale and should be reconciled to the SEC filing before relying on the balance-sheet thesis. Over the next 1-3 months, the stock is vulnerable to any evidence that consensus estimates are being maintained on promotional assumptions rather than revised customer demand; unchanged estimates after a sharp rerating are not a positive catalyst. Over 6-18 months, the decisive datapoints are external InP revenue growth versus internal supply ramps at COHR/LITE, gross-margin progression, capex intensity and whether prepayments convert into recurring orders.

Key Decisions for Investors

• Do not add directional AXTI exposure until the reported cash balance, secondary-offering proceeds and share count are verified in the latest 10-Q/8-K; a discrepancy would materially change dilution, enterprise value and capacity-funding assumptions.
• Establish an alert for AXTI's next earnings release: reduce/short on a gross-margin decline of more than 300 bps, a material increase in capex without corresponding backlog conversion, or any indication that customer prepayments are not binding take-or-pay commitments. The expected downside setup is multiple compression rather than near-term revenue collapse.
• For a relative-value expression after liquidity and borrow are confirmed, favor short AXTI versus long COHR in equal beta-adjusted dollars over 6-12 months. COHR captures AI-optics demand while its vertical integration reduces exposure to merchant-wafer pricing; invalidate the pair if AXTI demonstrates sustained external InP growth and stable/increasing gross margin through two consecutive capacity-ramp quarters.
• Treat LITE as a watch-list beneficiary rather than a standalone long solely on this thesis: evidence that its internal fabs reach qualified volume could support margins and supply security, but the same development is adverse to AXTI's merchant demand. Monitor LITE optical-networking guidance and internal-versus-external substrate sourcing commentary at each earnings call.